Shannon L. Wiley, Michael R. Hess

Although free drug starter programs are commonplace in the specialty pharmacy space, they vary widely in the marketplace.

Navigating insurance coverage for specialty drugs has always been a complex and fundamental part of the specialty drug distribution chain.

Specialty pharmacies will need to carefully consider the effect of the final rule regarding Anti-Kickback Statute safe harbors and Civil Monetary Penalty Law exceptions on their existing patient benefit programs.

As new biosimilars enter the market, pharmacies should carefully consider infrastructure, resources, and strategies for successfully integrating the products into their portfolio of offerings.

Specialty pharmacies should not let the new trend of enforcement on day-to-day operations fly under their radar.